**Appendix Table E117. Results from studies assessing the ability of miscellaneous platelet function tests to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease**

| **Author, year****UID****Country****Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Reactivity Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., HPR+ or HPR−)** | **No. with outcome status within phenotype group** | **Cut-off** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)****[statistical test]** | **Adjusted?****[YES/NO/NR]****If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dziewierz,200515815794Poland NR | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation  | DPAI | The degree of platelet aggregation  | 3h | Non-responder  | Non-responder  | 15/31 (48.4) | 10% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | responder  | responder  | 16/31 (51.6) |  |  |  |  |  |  |  |
|  | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation  | DPAI | The degree of platelet aggregation  | 6h | Non-responder  | Non-responder  | 8/31 (25.8) | 10% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | responder  | responder  | 23/31 (74.2) |  |  |  |  |  |  |  |
|  | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation  | DPAI | The degree of platelet aggregation  | 12h | Non-responder  | Non-responder  | 8/31 (25.8) | 10% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | responder  | responder  | 23/31 (74.2) |  |  |  |  |  |  |  |
|  | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation  | DPAI | The degree of platelet aggregation  | 24h | Non-responder  | Non-responder  | 7/31 (22.6) | 10% | NR | NR | 1.0 (fishers exact between categories) | NR | NR |  |
|  |  |  |  |  |  | responder  | responder  | 24/31 (77.4) |  |  |  |  |  |  |  |
| Lindvall,200919477870SwedenNone | 300-600mg LD Clopidogrel and MD 75 mg/day+75mg daily aspirin | ADP-induced aggregation | Clopidogrel response vs nonresponse | Response defined as >90% aggregation | Repeat measurement immediately after aprotinin | Baseline HPR+N = 4 | HPR-  | 1 | >90% | NR | NR | 0.07(fishers exact between categories) | NR | NR |  |
|  |  |  |  |  |  | Baseline HPR- N = 11 | HPR+  | 2 |  |  |  |  |  |  |  |
| Gurbel ,200312714161USANo | 300mg LD clopidogrel and 75mg daily MD with 325 mg/day aspirin | Flow cytometry for P-selectin expression | Continued nonresponse since baseline | NR | 5 days | Nonresponders at baseline (n=9) | Nonresponders at 5 days | 5/9 (56%) | <10% change from baseline | NR | NR | 0.144 (fishers exact between categories) | NR | NR | NONE |
|  |  |  |  |  | 5 days | Responders at baseline (n=29) | Responders at 5 days | 29/29 (100%) |  |  |  |  |  |  |  |
|  |  |  |  |  | 30 days | Nonresponders at baseline (n=9) | Nonresponders at 30 days | 3/6 (50%) with data (3 were not measured at 30 days) |  |  |  |  |  |  |  |
|  |  |  |  |  | 30 days | Responders at baseline (n=29) | Responders at 30 days | 14/18 (78%) with data (11 were not measured at 30 days) |  |  |  |  |  |  |  |
| Kalantzi, 201221806493Greece | LD 600mg clopidogrel+MD 75 mg/day | CD40L, PMP, FACSCalibur flow cytometer | CD40L, PMP, FACSCalibur flow cytometer | CD40L, PMP, FACSCalibur flow cytometer | 30 days | responder | responder by PRI >50% | 12 | NR | NR | NR | NR | NR | NR | figure 1, 2 |
|  |  |  |  |  | 30 days | non-responder |  | 28 |  |  |  |  |  |  |  |